Please assess the completion status of the following clinical trial:

Trial Title: Study of TAK-672 in Participants With Acquired Hemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female Japanese participants of \>=18 years of age.~2. Participants who (or their legally authorized representatives) have provided his/her written informed consent form prior to any study-related procedures and study product administration.~3. Participants with a diagnosis of AHA based on clinical evaluation and supportive local laboratory testing as shown below:~   * Presentation with spontaneous bleeding without anatomical cause and without prior known bleeding disorder.~  * Prolonged activated partial thromboplastin time (aPTT) without explanation.~  * Abnormal aPTT cross mixing test consistent with FVIII inhibitors~  * Confirmation of a low FVIII:C.~  * Positive FVIII inhibitor (\>=0.6 BU) as measured either in the local or central laboratory~4. Participants with a severe bleeding episode which the investigator finds necessary to treat and whose severe bleeding episode meets at least 1 of the following criteria:~   * Bleeds that pose a threat to a vital organ that could threaten life (e.g. intracranial bleed, or any site that could obstruct the airway).~  * Bleeds that pose a threat to a vital organ where life is not threatened but the organ function could be impaired (e.g., intraspinal bleed threatening the spinal cord and/or nerve conduction; a continual bleed into the kidney or bladder that could result in an obstructive uropathy, testicular bleed, bleed in and around the eye).~  * Bleeds requiring a blood transfusion to maintain the Hgb level at above-life or organ threatening levels (e.g. post-surgical, gastro-intestinal, retro-peritoneal, and thigh bleeds).~  * Intramuscular bleeds where muscle viability and/or neurovascular integrity is significantly compromised or at risk of being compromised.~  * Intra-articular bleeds impacting a major joint associated with severe pain, swelling and severe loss of joint mobility (reduced \>70%) or where a bleed could result in joint destruction (e.g. in and around the femoral head).~5. Participants who are taking anti-thrombotics (including anti-platelet agents and anticoagulantswith confirmatory laboratory testing documenting specific FVIII inhibitor titer and with 3 half-lives of the agent have elapsed since the last dose.~6. Participants with expected life expectancies of at least 90 days prior to the onset of the hemorrhagic episode.~7. Participants of reproductive age who have agreed to use acceptable methods of contraception and if female, undergo pregnancy testing as part of the screening process.~8. Participant who are able to willing and able to comply with the requirements of the protocol.~Exclusion Criteria:~1. Participants with an established reason for bleeding that is not correctable even with hemostatic therapy.~2. Participants presenting a bleeding episode that is assessed likely to resolve on its own, even if left untreated.~3. Participants with a known major sensitivity (anaphylactoid reactions) to therapeutic products of porcine or hamster origin; examples include therapeutics of porcine origin (e.g. previously marketed porcine FVIII, Hyate: C) and recombinant therapeutics prepared from hamster cells (e.g. Humira, Advate, and Enbrel).~4. Participants with the use of hemophilia medication: prior to the administration of TAK-672 under one of the following conditions: (1) use of recombinant activated factor VII (rFVI)Ia  within 3 hours prior to TAK-672 administration (2) use of  activated prothrombin complex concentrate (aPCC) within 6 hours prior to TAK-672 administration or (3) use of  plasma-derived FX/FVIIa complex concentrate (pd-FX/FVIIa)  within 8 hours prior to TAK-672 administration.~5. Participants with an anticipated need for treatment or device during the study that may interfere with the evaluation of the safety or efficacy of TAK-672, or whose safety or efficacy may be affected by TAK-672.~6. Participants who are currently pregnant or breastfeeding, or planning to become pregnant or father a child during the study~7. Participants who have participated in another clinical study and has been exposed to an investigational product or device within 30 days prior to the study enrollment.~8. Participants who are scheduled to participate in another non-observational (interventional) clinical study involving an investigational product or device during the course of the study.~9. Participants who are unable to or unwilling to comply with the study design, protocol requirements, and/or the follow-up procedures.~10. Participants whose majority of age are under legal protection.~11. Participants who are an immediate family member, study site employee, or are in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g. spouse, parent, child, sibling) or may consent under duress.~12. Participants who are judged by the investigator as being ineligible for any other reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAK-672 (Type: EXPERIMENTAL): TAK-672 was administered at an initial dose of 200 U/kg with IV infusion at a rate of 1-2 mL/min at Day 1. Subsequent doses were determined based on the post-infusion FVIII:C achieved after the most recent dose given, the target FVIII:C, and pFVIII inhibitor titer.

Based on this trial design, predict the completion outcome and termination type (if applicable).